je.st
news
Tag: study results
PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients
2014-05-13 11:58:44| Logistics - Topix.net
The EVOLVE trial is a phase I/II trial of intravenous administration of enadenotucirev to patients with epithelial cancers and the MoA trial is a phase I "window of opportunity" trial evaluating intravenous and intra-tumoural administration of enadenotucirev to patients with colon cancer.
Tags: results
study
release
cancer
Gilead Announces Results from Phase 2 Study Showing Reduction in...
2014-05-11 00:54:46| Biotech - Topix.net
Gilead Sciences, Inc. today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden in patients with paroxysmal atrial fibrillation .
Tags: in
results
showing
study
Weekly Overview: UK Publishes Results of Study into Pig-Human Health Concerns
2014-03-17 01:00:00| ThePigSite - Industry News
GLOBAL - Last week, the results were presented of a study of a number of potential animal and human health concerns in slaughter pigs in the UK, writes Jackie Linden.
Tags: results
health
study
overview
New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
2014-03-05 18:15:00| Merck.com - Product News
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today that in a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-nave patients one containing Mercks twice-daily ISENTRESS (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of efficacy, as measured by time to virologic failure (V Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
large
study
Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
2014-03-04 23:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
house
study
phase